~~<i id='6BF0D81DA7'><strike id='6BF0D81DA7'><tt id='6BF0D81DA7'><pre id='6BF0D81DA7'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

knowledge

entertainment

author：entertainment 2025-09-05 09:17:03 - browse：769

Roche’s announcement Monday that it would pay $310 million for rights to a hypertension treatment, zilebesiran, invented by the biotech firm Alnylam is evidence of a renewed interest on the part of large pharmaceutical companies for treatments for cardiovascular disease.

If things go well, Roche could pay Alnylam up to $2.8 billion in total.

Heart drugs were once the most lucrative category of pharmaceuticals, but they have been eclipsed by treatments for cancer and other diseases as drug firms have struggled to one-up existing treatments for high blood pressure and high cholesterol that are now available as cheap generics.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Wildfire smoke exposes gaps in outdoor worker protections
Next article： Coercive sterilizations revealed by STAT prompt outrage

focus

hotspot

focus

explore

knowledge

Wikipedia

JulioCortez/APThepharmaceuticalindustryhasfollowedabrillianttwo-prongedstrategytomaximizeitsprofits:

WSS

How faith leaders like me can help address America's obesity epidemic

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Insurer loopholes limit power of law against surprise medical bills

Curing rare childhood diseases will falter unless Congress steps up

California wildfire smoke linked to 52,000 early deaths, study says

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

knowledge

entertainment

focus

Hollywood unions extend contract negotiations for actors

Researchers test human milk's ability to repair gut microbiome

In age of alternative facts, a scholarly course on calling out crap

Scientists uncover potential path to treating deadly childhood tumor

Drug repurposing or repositioning? The language matters

Oral obesity drug from Viking Therapeutics hits key early target

Tori Bowie and the unacceptable rates of Black maternal death

Curing rare childhood diseases will falter unless Congress steps up

Wildfire smoke exposes gaps in outdoor worker protections

First Opinion on colorectal cancer screening: letter and response

hotspot

NIH tests clinical research in primary care with $30 million program

Report captures long Covid’s disabling effects and policy challenges

Gut bacteria may contribute to kidney autoimmunity, study finds

Depression: FDA OKs Otsuka Pharmaceuticals digital therapeutic

Young boy dies in trial for Pfizer Duchenne gene therapy

Multiple sclerosis has subtypes with different best treatments: study

focus

explore

knowledge

Wikipedia